ABSTRACT
BACKGROUND: There is a growing number of cohorts and registries collecting phenotypic and genotypic data from groups of multiple sclerosis patients. Improved awareness and better coordination of these efforts is needed. OBJECTIVE: The purpose of this report is to provide a global landscape of the major longitudinal MS patient data collection efforts and share recommendations for increasing their impact. METHODS: A workshop that included over 50 MS research and clinical experts from both academia and industry was convened to evaluate how current and future MS cohorts could be better used to provide answers to urgent questions about progressive MS. RESULTS: The landscape analysis revealed a significant number of largely uncoordinated parallel studies. Strategic oversight and direction is needed to streamline and leverage existing and future efforts. A number of recommendations for enhancing these efforts were developed. CONCLUSIONS: Better coordination, increased leverage of evolving technology, cohort designs that focus on the most important unanswered questions, improved access, and more sustained funding will be needed to close the gaps in our understanding of progressive MS and accelerate the development of effective therapies.
Subject(s)
Guidelines as Topic , Multiple Sclerosis/epidemiology , Multiple Sclerosis/therapy , Registries/standards , Capital Financing , Cohort Studies , Consensus Development Conferences as Topic , Disease Progression , Electronic Health Records , Genotype , Humans , Immunomodulation , Multiple Sclerosis/economics , Multiple Sclerosis/genetics , Phenotype , Prevalence , Research , Treatment OutcomeABSTRACT
The US National Institute of Neurological Disorders and Stroke convened major stakeholders in June 2012 to discuss how to improve the methodological reporting of animal studies in grant applications and publications. The main workshop recommendation is that at a minimum studies should report on sample-size estimation, whether and how animals were randomized, whether investigators were blind to the treatment, and the handling of data. We recognize that achieving a meaningful improvement in the quality of reporting will require a concerted effort by investigators, reviewers, funding agencies and journal editors. Requiring better reporting of animal studies will raise awareness of the importance of rigorous study design to accelerate scientific progress.
Subject(s)
Publishing/standards , Research Design/standards , Animals , Publishing/trends , Random Allocation , Sample Size , Statistics as TopicSubject(s)
Gene Products, tax/history , HLA-A2 Antigen/history , Peptide Fragments/history , Receptors, Antigen, T-Cell, alpha-beta/history , Crystallography, X-Ray/history , Gene Products, tax/chemistry , Gene Products, tax/metabolism , HLA-A2 Antigen/chemistry , HLA-A2 Antigen/metabolism , History, 20th Century , Humans , Models, Molecular , Peptide Fragments/chemistry , Peptide Fragments/metabolism , Protein Binding/immunology , Receptors, Antigen, T-Cell, alpha-beta/chemistry , Receptors, Antigen, T-Cell, alpha-beta/metabolism , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/metabolism , T-Lymphocytes, Cytotoxic/virologyABSTRACT
This workshop examined the opportunities for translational research directed at immune and inflammatory mechanisms. This summary presents the background data in 3 general areas: (1) inflammation and hemostasis in cerebrovascular and cardiovascular disease, (2) immune interactions in the central nervous system and heart, and (3) translation of immune modulation in the brain and heart, all of which supported a consensus derivation of the opportunities for future research in these areas. The summary concludes with 11 recommendations.
Subject(s)
Education/methods , Immunologic Factors/therapeutic use , Vascular Diseases/immunology , Vascular Diseases/prevention & control , Animals , Brain/immunology , Cerebrovascular Disorders/immunology , Cerebrovascular Disorders/prevention & control , Heart/physiology , Heart Diseases/immunology , Heart Diseases/prevention & control , Humans , MarylandABSTRACT
A potential public health concern is the reported detection of the human T-lymphotropic virus (HTLV) tax gene in the lymphocytes of up to 11% of a low-risk group of New York City blood donors (NYBD). This study aimed to independently confirm the prevalence of HTLV tax sequences in 293 NYBD. All NYBD tested negative for antibodies to HTLV types 1 and 2 and HTLV Tax. HTLV tax sequences were not detected in the NYBD lymphocytes. These data demonstrate the lack of HTLV-1 tax in this group of NYBD at low risk for HTLV infection.
Subject(s)
Blood Donors , Genes, pX , HTLV-I Antibodies/blood , HTLV-I Infections/diagnosis , HTLV-II Antibodies/blood , HTLV-II Infections/diagnosis , Human T-lymphotropic virus 1/isolation & purification , Human T-lymphotropic virus 2/isolation & purification , Lymphocytes/virology , Adult , Antibody Specificity , Female , Gene Products, tax/immunology , HTLV-I Antibodies/immunology , HTLV-I Infections/blood , HTLV-I Infections/epidemiology , HTLV-II Antibodies/immunology , HTLV-II Infections/blood , HTLV-II Infections/epidemiology , Human T-lymphotropic virus 1/genetics , Human T-lymphotropic virus 1/immunology , Human T-lymphotropic virus 2/genetics , Human T-lymphotropic virus 2/immunology , Humans , Immunoenzyme Techniques , Male , New York City/epidemiology , Polymerase Chain Reaction , Prevalence , Risk FactorsABSTRACT
T cells recognizing self or microbial antigens may trigger or reactivate immune-mediated diseases. Monitoring the frequency of specific T cell clonotypes to assess a possible link with the course of disease has been a difficult task with currently available technology. Our goal was to track individual candidate pathogenic T cell clones, selected on the basis of previous extensive studies from patients with immune-mediated disorders of the CNS, including multiple sclerosis, HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) and chronic Lyme neuroborreliosis. We developed and applied a highly specific and sensitive technique to track single CD4(+) and CD8(+) T cell clones through the detection and quantification of T cell receptor (TCR) alpha or beta chain complementarity-determining region 3 transcripts by real-time reverse transcriptase (RT)-PCR. We examined the frequency of the candidate pathogenic T cell clones in the peripheral blood and CSF during the course of neurological disease. Using this approach, we detected variations of clonal frequencies that appeared to be related to clinical course, significant enrichment in the CSF, or both. By integrating clonotype tracking with direct visualization of antigen-specific staining, we showed that a single T cell clone contributed substantially to the overall recognition of the viral peptide/MHC complex in a patient with HAM/TSP. T cell clonotype tracking is a powerful new technology enabling further elucidation of the dynamics of expansion of autoreactive or pathogen-specific T cells that mediate pathological or protective immune responses in neurological disorders.